Home » Stocks » APLS

Apellis Pharmaceuticals, Inc. (APLS)

Stock Price: $46.48 USD -1.71 (-3.55%)
Updated May 6, 2021 4:00 PM EDT - Market closed
After-hours: $46.48 0.00 (0.00%) May 6, 4:02 PM
Market Cap 3.70B
Revenue (ttm) 250.65M
Net Income (ttm) -359.71M
Shares Out 79.22M
EPS (ttm) -4.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $46.48
Previous Close $48.19
Change ($) -1.71
Change (%) -3.55%
Day's Open 48.08
Day's Range 45.49 - 48.63
Day's Volume 643,077
52-Week Range 25.49 - 58.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Apellis' (APLS) earnings lag estimates in the first quarter of 2021. Main focus of the company is on its lead pipeline candidate, pegcetacoplan.

1 week ago - Zacks Investment Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -37.28% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for th...

1 week ago - Zacks Investment Research

WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its first quarter...

1 week ago - GlobeNewsWire

Apellis Pharmaceuticals, Inc. (APLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 week ago - Zacks Investment Research

NEW YORK, April 26, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty c...

1 week ago - PRNewsWire

WALTHAM, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company...

2 weeks ago - GlobeNewsWire

WALTHAM, Mass., April 16, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that 10 abstract...

2 weeks ago - GlobeNewsWire

With the trading day about halfway over, the broad markets were trading sideways into the weekend, despite the Dow Jones industrials and the S&P 500 setting record intraday highs in the session.

Other stocks mentioned: AMZN, CMG, DIS, ARRY, BE, JKS
2 weeks ago - 24/7 Wall Street

WALTHAM, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced 24-month data fro...

3 weeks ago - GlobeNewsWire

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

WALTHAM, Mass. and STOCKHOLM, March 17, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the New Engla...

1 month ago - GlobeNewsWire

WALTHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) --   Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that two leadi...

1 month ago - GlobeNewsWire

WALTHAM, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company ...

2 months ago - GlobeNewsWire

Following an interim review of mortality data by an independent data monitoring committee (DMC), Apellis Pharmaceuticals Inc (NASDAQ: APLS) will not pursue additional development of APL-9 for the treatm...

2 months ago - Benzinga

WALTHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company ...

2 months ago - GlobeNewsWire

Apellis' (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. Main focus of the company is on lead pipeline candidate, pegcetacoplan.

2 months ago - Zacks Investment Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of 293.75% and 35.47%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for t...

2 months ago - Zacks Investment Research

WALTHAM, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company ...

2 months ago - GlobeNewsWire

WALTHAM, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company a...

3 months ago - GlobeNewsWire

WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its ...

3 months ago - GlobeNewsWire

WALTHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company w...

3 months ago - GlobeNewsWire

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered...

3 months ago - GlobeNewsWire

Apellis' (APLS) lead pipeline candidate, pegcetacoplan, is a promising one and being developed for several indications.

4 months ago - Zacks Investment Research

STOCKHOLM and WALTHAM, Mass., Dec. 10, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals Inc. (Nasdaq: APLS) today announced positive top-line result...

4 months ago - PRNewsWire

WALTHAM, Mass. and STOCKHOLM, Sweden, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi™ Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced posit...

4 months ago - GlobeNewsWire

WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company a...

5 months ago - GlobeNewsWire

WALTHAM, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company ...

5 months ago - GlobeNewsWire

Apellis (APLS) and Sobi dose the first patient in the mid-stage MERIDIAN study, which is investigating pegcetacoplan to address adults with sporadic amyotrophic lateral sclerosis.

5 months ago - Zacks Investment Research

STOCKHOLM and WALTHAM, Mass., Nov. 19, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (SobiTM) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the first patient...

5 months ago - PRNewsWire

WALTHAM, Mass. and STOCKHOLM, Sweden, Nov. 19, 2020 (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the f...

5 months ago - GlobeNewsWire

The FDA accepts Apeliis' (APLS) NDA for pegcetacoplanand and grants priority review for the treatment of paroxysmal nocturnal hemoglobinuria.

5 months ago - Zacks Investment Research

WALTHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S. Foo...

5 months ago - GlobeNewsWire

WALTHAM, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced findings from the...

5 months ago - GlobeNewsWire

WALTHAM, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company ...

5 months ago - GlobeNewsWire

WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that eight abstra...

6 months ago - GlobeNewsWire

Apellis (APLS) reports a wider-than-expected loss in the third quarter of 2020.

6 months ago - Zacks Investment Research

WALTHAM, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its third quarter ...

6 months ago - GlobeNewsWire

WALTHAM, Mass. and STOCKHOLM, Sweden, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced a strategic...

6 months ago - GlobeNewsWire

WALTHAM, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced 18-month data from...

6 months ago - GlobeNewsWire

WALTHAM, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that positive resu...

6 months ago - GlobeNewsWire

WALTHAM, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company appr...

6 months ago - GlobeNewsWire

WALTHAM, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has initia...

7 months ago - GlobeNewsWire

WALTHAM, Mass., Oct. 03, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the results of a p...

7 months ago - GlobeNewsWire

WALTHAM, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the comp...

7 months ago - GlobeNewsWire

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that a post hoc...

7 months ago - GlobeNewsWire

Apellis (APLS) submits an NDA to the FDA and an MAA to the European Medicines Agency for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria.

7 months ago - Zacks Investment Research

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago.

8 months ago - Zacks Investment Research

WALTHAM, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its second qu...

9 months ago - GlobeNewsWire

Apellis Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

9 months ago - Seeking Alpha

WALTHAM Mass., July 07, 2020 (GLOBE NEWSWIRE) --   Apellis Pharmaceuticals  Inc., (NASDAQ:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it completed ...

9 months ago - GlobeNewsWire

About APLS

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous n... [Read more...]

Industry
Biotechnology
IPO Date
Nov 9, 2017
CEO
Cedric Francois
Employees
374
Stock Exchange
NASDAQ
Ticker Symbol
APLS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 15 analysts, the average rating for APLS stock is "Buy." The 12-month stock price forecast is 70.40, which is an increase of 51.46% from the latest price.

Price Target
$70.40
(51.46% upside)
Analyst Consensus: Buy